对震主导的帕金森病单侧聚焦超声波切除术:盲目评估和成像相关性
James Peters1,2, Joel Maamary1,2, Kain Kyle3
1Department of Neurology, St Vincent's Health Network, Darlinghurst, New South Wales 2010, Australia.
Brain communications
|September 2, 2025
概括
单侧高强度聚焦超声波 (HiFUS) 治疗可缓解大约一半的帕金森病患者的震. 然而,结果与病变大小或通道重叠无关,这表明帕金森病的最佳标不同.
科学领域:
- 神经外科
- 神经学
- 医学成像
背景情况:
- 单侧高强度聚焦超声波 (HiFUS) 治疗震主导的帕金森病 (PD) 是有前途的.
- 震复发率高,使人们对治疗可靠性和病变大小产生疑问.
- 需要详细的体积损伤分析来了解治疗失败的机制.
研究的目的:
- 在震占主导地位的PD中评估单侧HiFUS胸膜切除的失明震结果.
- 将结果与病变特征关联起来,包括牙和胸膜管 (DRTT) 的重叠.
- 通过调查震复发机制来精确PD震的最佳HiFUS目标.
主要方法:
- 对17名震主导的PD患者进行了回顾,这些患者接受了单侧HiFUS乳房切除手术.
- 使用手术前和手术后视频进行盲目震分析 (分析了15名患者).
- 分类为"响应者" (手震得分改善≥50%) 和"低于最佳响应者"组.
主要成果:
- 的中位数有所改善,但有7名患者有反应 (≥50%的改善),而8名患者的反应不足.
- 响应者显示中位数震得分有91%的改善,而未达到最佳响应者则有8%的增加 (P < 0. 002).
- 在未达到最佳反应的患者中观察到较大的病变和较大的DRTT重叠 (P=0.010),与震改善无关.
结论:
- 在大约50%的PD患者中,单侧HiFUS胸膜切除可以持续减少震.
- 良好的结果与DRTT切除重叠或病变大小没有相关性.
- 结果表明PD震的最佳HiFUS目标可能与基本震不同.
相关概念视频
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702


